Fig. 3From: Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMSLongitudinal effect of laquinimod (LAQ) on slanDC and monocytes. Sample sizes for placebo n = 5, sample sizes for laquinimod n = 12. BL baseline, Freq frequency, PBMC peripheral blood mononuclear cell, slanDC 6-sulpho LacNAc+ dendritic cell, W week, WO washoutBack to article page